Cytokine-induced tumor suppressors: A GRIM story

Cytokine

Volumn 52, Issue 1-2, 2010, Pages 128-142

  Kalvakolanu, Dhan V ^a   Nallar, Shreeram C ^a   Kalakonda, Sudhakar ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytokines; Transcriptional inhibition and immune response; Tumor suppressors

Indexed keywords

GRIM 19 PROTEIN; INTERFERON; RETINOIC ACID; RETINOL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; GRIM19 PROTEIN, HUMAN; OXIDOREDUCTASE;

ANTINEOPLASTIC ACTIVITY; BACTERIUM; CANCER INHIBITION; CELL DEATH; CELL GROWTH; DRUG POTENTIATION; GENE; GENE ISOLATION; GENE SILENCING; GRIM 19 GENE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TUMOR CELL; VIRUS; ANIMAL; GENETIC ASSOCIATION; GENETICS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; GENE KNOCKDOWN TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERFERONS; NADH, NADPH OXIDOREDUCTASES; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 79952108141     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.03.009     Document Type: Review

References (255)

1. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73:2013-2026.
2. Czerski L., Nunez G. Apoptosome formation and caspase activation: is it different in the heart?. J Mol Cell Cardiol 2004, 37:643-652.
3. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
4. Guicciardi M.E., Gores G.J. Life and death by death receptors. FASEB J 2009, 23:1625-1637.
5. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
6. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
7. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
8. Kelekar A., Thompson C.B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998, 8:324-330.
9. Huang D.C., Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000, 103:839-842.
10. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4:327-332.
11. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
12. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
13. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
14. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995, 80:285-291.
15. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.
16. Kelekar A., Chang B.S., Harlan J.E., Fesik S.W., Thompson C.B. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol Cell Biol 1997, 17:7040-7046.
17. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol 1999, 1:E33-E35.
18. Harada H., Becknell B., Wilm M., Mann M., Huang L.J., Taylor S.S., et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 1999, 3:413-422.
19. Billen L.P., Shamas-Din A., Andrews D.W. Bid: a Bax-like BH3 protein. Oncogene 2008, 27(Suppl. 1):S93-S104.
20. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
21. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
22. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003, 116:4077-4085.
23. Chipuk J.E., Green D.R. Dissecting p53-dependent apoptosis. Cell Death Differ 2006, 13:994-1002.
24. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim Biophys Acta 2009, 1787:414-420.
25. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 2010, 20:14-24.
26. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
27. Cheng E.H., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278:1966-1968.
28. Clem R.J., Cheng E.H., Karp C.L., Kirsch D.G., Ueno K., Takahashi A., et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998, 95:554-559.
29. Kalvakolanu D.V., Borden E.C. Interferons: cellular and molecular biology of their actions. Encyclopedia of cancer 2002, 511-521. Academic Press, San Diego, CA. J.R. Bertino (Ed.).
30. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
31. Sen G.C. Viruses and interferons. Annu Rev Microbiol 2001, 55:255-281.
32. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
33. Basler C.F., Amarasinghe G.K. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009, 29:511-520.
34. Beglin M., Melar-New M., Laimins L. Human papillomaviruses and the interferon response. J Interferon Cytokine Res 2009, 29:629-635.
35. Diamond M.S. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J Interferon Cytokine Res 2009, 29:521-530.
36. Gale M., Sen G.C. Viral evasion of the interferon system. J Interferon Cytokine Res 2009, 29:475-476.
37. George C.X., Li Z., Okonski K.M., Toth A.M., Wang Y., Samuel C.E. Tipping the balance. Antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products. J Interferon Cytokine Res 2009, 29:477-487.
38. Horner S.M., Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009, 29:489-498.
39. Lee H.R., Kim M.H., Lee J.S., Liang C., Jung J.U. Viral interferon regulatory factors. J Interferon Cytokine Res 2009, 29:621-627.
40. Marshall E.E., Geballe A.P. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res 2009, 29:609-619.
41. Neil S., Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009, 29:569-580.
42. Paladino P., Mossman K.L. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res 2009, 29:599-607.
43. Perdiguero B., Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009, 29:581-598.
44. Ramachandran A., Horvath C.M. Paramyxovirus disruption of interferon signal transduction: status report. J Interferon Cytokine Res 2009, 29:531-537.
45. Sherry B. Rotavirus and reovirus modulation of the interferon response. J Interferon Cytokine Res 2009, 29:559-567.
46. Wolff T., Ludwig S. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. J Interferon Cytokine Res 2009, 29:549-557.
47. Reed C.J. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol 2000, 37:9-16.
48. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
49. Golstein P., Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007, 32:37-43.
50. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
51. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8:741-752.
52. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat Rev Cancer 2007, 7:961-967.
53. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795.
54. Kalvakolanu D.V. Interferons and cell growth control. Histol Histopathol 2000, 15:523-537.
55. Sen G.C. Novel functions of interferon-induced proteins. Semin Cancer Biol 2000, 10:93-101.
56. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
57. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
58. Fujita T., Kimura Y., Miyamoto M., Barsoumian E.L., Taniguchi T. Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature 1989, 337:270-272.
59. Pine R., Decker T., Kessler D.S., Levy D.E., Darnell J.E. Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either. Mol Cell Biol 1990, 10:2448-2457.
60. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263:1612-1615.
61. Contursi C., Wang I.M., Gabriele L., Gadina M., O'Shea J., Morse H.C., et al. IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages. Proc Natl Acad Sci USA 2000, 97:91-96.
62. Ozato K., Tailor P., Kubota T. The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 2007, 282:20065-20069.
63. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
64. Shuai K., Schindler C., Prezioso V.R., Darnell J.E. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992, 258:1808-1812.
65. Aoki N., Matsuda T. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 2002, 16:58-69.
66. ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M., David M., et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002, 22:5662-5668.
67. Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997, 278:1803-1805.
68. Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998, 95:10626-10631.
69. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
70. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001, 28:29-35.
71. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004, 22:503-529.
72. Gresser I., Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002, 13:111-118.
73. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1:447-456.
74. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005, 6:722-729.
75. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95:7556-7561.
76. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
77. Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., Slovak M.L., et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993, 259:968-971.
78. Holtschke T., Lohler J., Kanno Y., Fehr T., Giese N., Rosenbauer F., et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996, 87:307-317.
79. Schmidt M., Nagel S., Proba J., Thiede C., Ritter M., Waring J.F., et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998, 91:22-29.
80. Hao S.X., Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000, 20:1149-1161.
81. Borden E.C., Lindner D., Dreicer R., Hussein M., Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000, 10:125-144.
82. Love J.M., Gudas L.J. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994, 6:825-831.
83. Bjelke E. Dietary vitamin A and human lung cancer. Int J Cancer 1975, 15:561-565.
84. Kuwata T., Wang I.M., Tamura T., Ponnamperuma R.M., Levine R., Holmes K.L., et al. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood 2000, 95:3349-3356.
85. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10:940-954.
86. Kliewer S.A., Umesono K., Mangelsdorf D.J., Evans R.M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355:446-449.
87. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
88. Nagpal S., Saunders M., Kastner P., Durand B., Nakshatri H., Chambon P. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992, 70:1007-1019.
89. Liu Y., Lee M.O., Wang H.G., Li Y., Hashimoto Y., Klaus M., et al. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996, 16:1138-1149.
90. Berard J., Laboune F., Mukuna M., Masse S., Kothary R., Bradley W.E. Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J 1996, 10:1091-1097.
91. de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
92. Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty V.V., et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
93. Chomienne C., Ballerini P., Balitrand N., Daniel M.T., Fenaux P., Castaigne S., et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990, 76:1710-1717.
94. Hofmann S.L. Retinoids - " differentiation agents" for cancer treatment and prevention. Am J Med Sci 1992, 304:202-213.
95. Chelbi-Alix M.K., Quignon F., Pelicano L., Koken M.H., de The H. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 1998, 72:1043-1051.
96. Nason-Burchenal K., Gandini D., Botto M., Allopenna J., Seale J.R., Cross N.C., et al. Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood 1996, 88:3926-3936.
97. Ruggero D., Wang Z.G., Pandolfi P.P. The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays 2000, 22:827-835.
98. Pelicano L., Li F., Schindler C., Chelbi-Alix M.K. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997, 15:2349-2359.
99. Regad T., Saib A., Lallemand-Breitenbach V., Pandolfi P.P., de The H., Chelbi-Alix M.K. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 2001, 20:3495-3505.
100. Dimberg A., Nilsson K., Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood 2000, 96:2870-2878.
101. Gianni M., Terao M., Fortino I., LiCalzi M., Viggiano V., Barbui T., et al. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997, 89:1001-1012.
102. Kolla V., Weihua X., Kalvakolanu D.V. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997, 272:9742-9748.
103. Matikainen S., Ronni T., Lehtonen A., Sareneva T., Melen K., Nordling S., et al. Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ 1997, 8:687-698.
104. Frey J.R., Peck R., Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 1991, 57:223-227.
105. Hemmi H., Breitman T.R. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987, 69:501-507.
106. Lindner D.J., Borden E.C., Kalvakolanu D.V. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997, 3:931-937.
107. Marth C., Daxenbichler G., Dapunt O. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 1986, 77:1197-1202.
108. Deiss L.P., Kimchi A. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science 1991, 252:117-120.
109. Hofmann E.R., Boyanapalli M., Lindner D.J., Weihua X., Hassel B.A., Jagus R., et al. Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 1998, 18:6493-6504.
110. Chidambaram N.V., Angell J.E., Ling W., Hofmann E.R., Kalvakolanu D.V. Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2000, 20:661-665.
111. Gao A.C., Lou W., Ichikawa T., Denmeade S.R., Barrett J.C., Isaacs J.T. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 1999, 38:46-54.
112. Angell J.E., Lindner D.J., Shapiro P.S., Hofmann E.R., Kalvakolanu D.V. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 2000, 275:33416-33426.
113. Fearnley I.M., Carroll J., Shannon R.J., Runswick M.J., Walker J.E., Hirst J. GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 2001, 276:38345-38348.
114. Murray J., Zhang B., Taylor S.W., Oglesbee D., Fahy E., Marusich M.F., et al. The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification. J Biol Chem 2003, 278:13619-136122.
115. Gillison M.L., Ambinder R.F. Human herpesvirus-8. Curr Opin Oncol 1997, 9:440-449.
116. Neipel F., Fleckenstein B. The role of HHV-8 in Kaposi's sarcoma. Semin Cancer Biol 1999, 9:151-164.
117. Moore P.S., Chang Y. Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet 1998, 14:144-150.
118. Burysek L., Pitha P.M. Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J Virol 2001, 75:2345-2352.
119. Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739-1744.
120. Burysek L., Yeow W.S., Lubyova B., Kellum M., Schafer S.L., Huang Y.Q., et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 1999, 73:7334-7342.
121. Li M., Damania B., Alvarez X., Ogryzko V., Ozato K., Jung J.U. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol 2000, 20:8254-8263.
122. Lin R., Genin P., Mamane Y., Sgarbanti M., Battistini A., Harrington W.J., et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 2001, 20:800-811.
123. Seo T., Lee D., Shim Y.S., Angell J.E., Chidambaram N.V., Kalvakolanu D.V., et al. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol 2002, 76:8797-8807.
124. Jayachandra S., Low K.G., Thlick A.E., Yu J., Ling P.D., Chang Y., et al. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci USA 1999, 96:11566-11571.
125. Zhou Y., Li M., Wei Y., Feng D., Peng C., Weng H., et al. Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res 2009, 29:695-703.
126. Guerra S., Lopez-Fernandez L.A., Pascual-Montano A., Munoz M., Harshman K., Esteban M. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol 2003, 77:6493-6506.
127. Greenaway P.J., Wilkinson G.W. Nucleotide sequence of the most abundantly transcribed early gene of human cytomegalovirus strain AD169. Virus Res 1987, 7:17-31.
128. Spector D.H. Activation and regulation of human cytomegalovirus early genes. Intervirology 1996, 39:361-377.
129. McSharry B.P., Tomasec P., Neale M.L., Wilkinson G.W. The most abundantly transcribed human cytomegalovirus gene (beta 2.7) is non-essential for growth in vitro. J Gen Virol 2003, 84:2511-2566.
130. Reeves M.B., Davies A.A., McSharry B.P., Wilkinson G.W., Sinclair J.H. Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science 2007, 316:1345-1348.
131. Zhang J., Yang J., Roy S.K., Tininini S., Hu J., Bromberg J.F., et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003, 100:9342-9347.
132. Lufei C., Ma J., Huang G., Zhang T., Novotny-Diermayr V., Ong C.T., et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003, 22:1325-1335.
133. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., et al. A novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71.
134. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
135. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
136. Bromberg J.F. Activation of STAT proteins and growth control. Bioessays 2001, 23:161-169.
137. Cattaneo E., Magrassi L., De-Fraja C., Conti L., Di Gennaro I., Butti G., et al. Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res 1998, 18:2381-2387.
138. Garcia R., Yu C.L., Hudnall A., Catlett R., Nelson K.L., Smithgall T., et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997, 8:1267-1276.
139. Gouilleux-Gruart V., Gouilleux F., Desaint C., Claisse J.F., Capiod J.C., Delobel J., et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996, 87:1692-1697.
140. Schrell U.M., Koch H.U., Marschalek R., Schrauzer T., Anders M., Adams E., et al. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M. J Neurosurg 1998, 88:541-548.
141. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
142. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001, 107:351-362.
143. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001, 7:517-528.
144. Ivanov V.N., Bhoumik A., Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161.
145. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
146. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947.
147. Dauer D.J., Ferraro B., Song L., Yu B., Mora L., Buettner R., et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24:3397-3408.
148. Dechow T.N., Pedranzini L., Leitch A., Leslie K., Gerald W.L., Linkov I., et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004, 101:10602-10607.
149. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005, 174:3925-3931.
150. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005, 175:4338-4346.
151. Kortylewski M., Jove R., Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005, 24:315-327.
152. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
153. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
154. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232.
155. Nielsen M., Kaestel C.G., Eriksen K.W., Woetmann A., Stokkedal T., Kaltoft K., et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999, 13:735-738.
156. Niu G., Shain K.H., Huang M., Ravi R., Bedi A., Dalton W.S., et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001, 61:3276-3280.
157. Gao L., Zhang L., Hu J., Li F., Shao Y., Zhao D., et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005, 11:6333-6341.
158. Munarriz E., Barcaroli D., Stephanou A., Townsend P.A., Maisse C., Terrinoni A., et al. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol 2004, 24:10593-10610.
159. Schmidt D., Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 2002, 99:2872-2877.
160. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 2005, 19:2671-2684.
161. Ungureanu D., Vanhatupa S., Kotaja N., Yang J., Aittomaki S., Janne O.A., et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 2003, 102:3311-3313.
162. Gross M., Liu B., Tan J., French F.S., Carey M., Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001, 20:3880-3887.
163. Junicho A., Matsuda T., Yamamoto T., Kishi H., Korkmaz K., Saatcioglu F., et al. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2000, 278:9-13.
164. Tan J.A., Hall S.H., Hamil K.G., Grossman G., Petrusz P., French F.S. Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators. J Biol Chem 2002, 277:16993-17001.
165. Iwamoto T., Senga T., Naito Y., Matsuda S., Miyake Y., Yoshimura A., et al. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 2000, 19:4795-4801.
166. Boulton T.G., Zhong Z., Wen Z., Darnell J.E., Stahl N., Yancopoulos G.D. STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc Natl Acad Sci USA 1995, 92:6915-6919.
167. Chung J., Uchida E., Grammer T.C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997, 17:6508-6516.
168. Schuringa J.J., Schepers H., Vellenga E., Kruijer W. Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 2001, 495:71-76.
169. Shen Y., Schlessinger K., Zhu X., Meffre E., Quimby F., Levy D.E., et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 2004, 24:407-419.
170. Kalakonda S., Nallar S.C., Lindner D.J., Hu J., Reddy S.P., Kalvakolanu D.V. Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res 2007, 67:6212-6220.
171. Zhang L., Gao L., Zhao L., Guo B., Ji K., Tian Y., et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007, 67:5859-5864.
172. Zhang L., Gao L., Li Y., Lin G., Shao Y., Ji K., et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res 2008, 14:559-568.
173. Ma X., Kalakonda S., Srinivasula S.M., Reddy S.P., Platanias L.C., Kalvakolanu D.V. GRIM-19 associates with the serine protease HtrA2 for promoting cell death. Oncogene 2007, 26:4842-4849.
174. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410.
175. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001, 410:112-116.
176. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002, 277:439-444.
177. Silke J., Hawkins C.J., Ekert P.G., Chew J., Day C.L., Pakusch M., et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J Cell Biol 2002, 157:115-124.
178. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001, 8:613-621.
179. van Loo G., van Gurp M., Depuydt B., Srinivasula S.M., Rodriguez I., Alnemri E.S., et al. The serine protease Omi/HtrA2 is released from
180. Palmisano G., Sardanelli A.M., Signorile A., Papa S., Larsen M.R. The phosphorylation pattern of bovine heart complex I subunits. Proteomics 2007, 7:1575-1583.
181. Maximo V., Botelho T., Capela J., Soares P., Lima J., Taveira A., et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005, 92:1892-1898.
182. Gupta S., Singh R., Datta P., Zhang Z., Orr C., Lu Z., et al. The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity. J Biol Chem 2004, 279:45844-45854.
183. Kuninaka S., Nomura M., Hirota T., Iida S., Hara T., Honda S., et al. The tumor suppressor WARTS activates the Omi/HtrA2-dependent pathway of cell death. Oncogene 2005, 24:5287-5298.
184. Zhang X., Huang Q., Yang Z., Li Y., Li C.Y. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004, 64:2474-2781.
185. Tomarev S.I., Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol Neurobiol 2009, 40:122-138.
186. Inomata H., Haraguchi T., Sasai Y. Robust stability of the embryonic axial pattern requires a secreted scaffold for chordin degradation. Cell 2008, 134:854-865.
187. Harland R.M. A protein scaffold plays matchmaker for chordin. Cell 2008, 134:718-719.
188. Kobayashi D., Koshida S., Moriai R., Tsuji N., Watanabe N. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci 2007, 98:334-340.
189. Zhang J., Liu W.L., Tang D.C., Chen L., Wang M., Pack S.D., et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 2002, 283:83-93.
190. Liu W., Chen L., Zhu J., Rodgers G.P. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res 2006, 312:1785-1797.
191. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28:2925-2939.
192. Hochegger H., Takeda S., Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all?. Nat Rev Mol Cell Biol 2008, 9:910-916.
193. Fung T.K., Poon R.Y. A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol 2005, 16:335-342.
194. Hunter T., Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582.
195. Brechot C. Oncogenic activation of cyclin A. Curr Opin Genet Dev 1993, 3:11-18.
196. Sherr C.J. D-type cyclins. Trends Biochem Sci 1995, 20:187-190.
197. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998, 1378:F115-F177.
198. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
199. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12:2245-2262.
200. Iaquinta P.J., Lees J.A. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007, 19:649-657.
201. Nevins J.R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258:424-429.
202. Haura E.B., Turkson J., Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005, 2:315-324.
203. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.
204. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
205. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83.
206. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998, 18:2553-2558.
207. Behrens J., Vakaet L., Friis R., Winterhager E., Van Roy F., Mareel M.M., et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993, 120:757-766.
208. Frame M.C. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004, 117:989-998.
209. Frame M.C., Fincham V.J., Carragher N.O., Wyke J.A. V-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002, 3:233-245.
210. Lin S.L., Garber E.A., Wang E., Caliguiri L.A., Schellekens H., Goldberg A.R., et al. Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol 1983, 3:1656-1664.
211. Perucho M., Esteban M. Inhibitory effect of interferon on the genetic and oncogenic transformation by viral and cellular genes. J Virol 1985, 54:229-232.
212. Kalakonda S., Nallar S.C., Gong P., Lindner D.J., Goldblum S.E., Reddy S.P., et al. Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels. Am J Pathol 2007, 171:1352-1368.
213. Martin G.S. The hunting of the Src. Nat Rev Mol Cell Biol 2001, 2:467-475.
214. Hakak Y., Hsu Y.S., Martin G.S. Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene 2000, 19:3164-3171.
215. Wu H., Parsons J.T. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993, 120:1417-1426.
216. Head J.A., Jiang D., Li M., Zorn L.J., Schaefer E.M., Parsons J.T., et al. Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. Mol Biol Cell 2003, 14:3216-3229.
217. Huang C., Ni Y., Wang T., Gao Y., Haudenschild C.C., Zhan X. Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J Biol Chem 1997, 272:13911-13915.
218. Tehrani S., Faccio R., Chandrasekar I., Ross F.P., Cooper J.A. Cortactin has an essential and specific role in osteoclast actin assembly. Mol Biol Cell 2006, 17:2882-2895.
219. Sun P., Nallar S.C., Kalakonda S., Lindner D.J., Martin S.S., Kalvakolanu D.V. GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene 2009, 28:1339-1347.
220. Ng D.C., Lin B.H., Lim C.P., Huang G., Zhang T., Poli V., et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006, 172:245-257.
221. Carroll J., Fearnley I.M., Skehel J.M., Shannon R.J., Hirst J., Walker J.E. Bovine complex I is a complex of 45 different subunits. J Biol Chem 2006, 281:32724-32727.
222. Huang G., Lu H., Hao A., Ng D.C., Ponniah S., Guo K., et al. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 2004, 24:8447-8456.
223. Vahsen N., Cande C., Briere J.J., Benit P., Joza N., Larochette N., et al. AIF deficiency compromises oxidative phosphorylation. EMBO J 2004, 23:4679-4689.
224. Lu H., Cao X. GRIM-19 is essential for maintenance of mitochondrial membrane potential. Mol Biol Cell 2008, 19:1893-1902.
225. Potla R., Koeck T., Wegrzyn J., Cherukuri S., Shimoda K., Baker D.P., et al. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 2006, 26:8562-8571.
226. Barnich N., Hisamatsu T., Aguirre J.E., Xavier R., Reinecker H.C., Podolsky D.K. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005, 280:19021-19026.
227. Kobayashi K., Inohara N., Hernandez L.D., Galan J.E., Nunez G., Janeway C.A., et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194-199.
228. Pauleau A.L., Murray P.J. Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 2003, 23:7531-7539.
229. Begum N.A., Ishii K., Kurita-Taniguchi M., Tanabe M., Kobayashi M., Moriwaki Y., et al. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect Immun 2004, 72:937-948.
230. Zhou Q., Amar S. Identification of proteins differentially expressed in human monocytes exposed to Porphyromonas gingivalis and its purified components by high-throughput immunoblotting. Infect Immun 2006, 74:1204-1214.
231. Bartholomay L.C., Cho W.L., Rocheleau T.A., Boyle J.P., Beck E.T., Fuchs J.F., et al. Description of the transcriptomes of immune response-activated hemocytes from the mosquito vectors Aedes aegypti and Armigeres subalbatus. Infect Immun 2004, 72:4114-4126.
232. Petty T.L. COPD in perspective. Chest 2002, 121:116S-120S.
233. Sethi J.M., Rochester C.L. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000, 21:67-86. viii.
234. Mayer A.S., Newman L.S. Genetic and environmental modulation of chronic obstructive pulmonary disease. Respir Physiol 2001, 128:3-11.
235. Ning W., Li C.J., Kaminski N., Feghali-Bostwick C.A., Alber S.M., Di Y.P., et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004, 101:14895-14900.
236. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
237. Ye H., Cande C., Stephanou N.C., Jiang S., Gurbuxani S., Larochette N., et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol 2002, 9:680-684.
238. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259-263.
239. Mehrabian Z., Chandrasekaran K., Kalakonda S., Kristian T., Fiskum G., Kalvakolanu D.V. The IFN-beta and retinoic acid-induced cell death regulator GRIM-19 is upregulated during focal cerebral ischemia. J Interferon Cytokine Res 2007, 27:383-392.
240. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
241. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
242. Alchanati I., Nallar S.C., Sun P., Gao L., Hu J., Stein A., et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006, 25:7138-7147.
243. Nindl I., Dang C., Forschner T., Kuban R.J., Meyer T., Sterry W., et al. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 2006, 5:30.
244. Gong L.B., Luo X.L., Liu S.Y., Tao D.D., Gong J.P., Hu J.B. Correlations of GRIM-19 and its target gene product STAT3 to malignancy of human colorectal carcinoma. Ai Zheng 2007, 26:683-687.
245. Vogel R.O., Dieteren C.E., van den Heuvel L.P., Willems P.H., Smeitink J.A., Koopman W.J., et al. Identification of mitochondrial complex I assembly intermediates by tracing tagged NDUFS3 demonstrates the entry point of mitochondrial subunits. J Biol Chem 2007, 282:7582-7590.
246. Chen Y., Yuen W.H., Fu J., Huang G., Melendez A.J., Ibrahim F.B., et al. The mitochondrial respiratory chain controls intracellular calcium signaling and NFAT activity essential for heart formation in Xenopus laevis. Mol Cell Biol 2007, 27:6420-6432.
247. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
248. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997, 237:1-6.
249. Kastan M.B., Lim D.S. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000, 1:179-186.
250. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112.
251. Lee R.J., Albanese C., Fu M., D'Amico M., Lin B., Watanabe G., et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000, 20:672-683.
252. Ohtani K., DeGregori J., Nevins J.R. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995, 92:12146-12150.
253. Lukas C., Sorensen C.S., Kramer E., Santoni-Rugiu E., Lindeneg C., Peters J.M., et al. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999, 401:815-818.
254. Onishi T., Zhang W., Cao X., Hruska K. The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependent kinase 1 (cdc2) in osteoblast precursors. J Bone Miner Res 1997, 12:1596-1605.
255. Kalvakolanu D.V. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev 2004, 15:169-194.